The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | ASH 2017 President’s meeting highlights
This year’s American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, presented major advances in hematology, with over 6,000 abstracts submitted. In this video, Kenneth Anderson, MD, of the Dana-Farber Cancer Institute, Boston, MA, this year’s ASH President, discusses the highlights of the meeting. Dr Anderson emphasizes the number of approved novel treatments and paradigm-changing agents, including those presented in late-breaking abstracts. He also draws attention to the focus on CAR T-cell therapy at the meeting this year, with this therapy now being investigated for many types of leukemia and lymphoma, as well as multiple myeloma, with impressive responses even in advanced disease.
